Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors. The invention also provides a method for detecting a Prostate Stem Cell Antigen (PSCA) protein of bone (SEQ ID NO:2), comprising obtaining a sample; contacting the sample with an antibody that recognizes and binds the PSCA protein; and, detecting binding of the antibody with the PSCA protein in the sample.
Type:
Grant
Filed:
May 3, 2000
Date of Patent:
April 1, 2003
Assignee:
The Regents of the University of California
Abstract: This invention provides a method of treating an animal with pyrophosphate gout or osteoarthritis comprising administering an effective amount of a calcium antagonist, thereby reducing calcium pyrophosphate crystal deposition in the animal.
Type:
Grant
Filed:
January 4, 2001
Date of Patent:
February 18, 2003
Assignee:
The Regents of the University of California
Abstract: The present invention relates to a nuclear transport agent, to a gene transfer system comprising said nuclear transport agent, to a method for transporting DNA into the nucleus of eukaryotic cells using said nuclear transport agent and to the use of said nuclear transport agent in gene therapy for treating cancer, viral infections, diseases of the nervous system, graft rejection and monogenic or polygenic hereditary diseases.
Abstract: Methods for inducing interleukin-12 production and inducing a type 1/Th1 T cell response in a subject, thereby stimulating cell-mediated immunity for prevention or treatment of pathogen infections or treatment of a interferon (-sensitive tumor, are provided. Compounds effective in the above-described methods include a lipopeptide having an N-terminal ester- or amide-linked fatty acyl group and are administered in an amount effective to induce interleukin-12 and to induce the type 1/Th1 T-cell response. Preferably, the subject is a human patient, and the lipopeptide is an N-terminal moiety of a 19 kDa or a 38 kDa lipoprotein of Mycobacterium tuberculosis.
Type:
Grant
Filed:
July 17, 1998
Date of Patent:
February 11, 2003
Assignee:
The Regents of the University of California
Abstract: The invention provides a DAX-1 protein molecule having the amino acid sequence beginning with methionine at position 1 and ending with isoleucine at position 470 as shown in FIG. 12. The invention further provides the genomic nucleic acid sequence for DAX-1, including intron, exons and a promoter region. Additionally, the invention provides methods for using and making the DAX-1 protein and DAX-1 nucleic acid molecules.
Type:
Grant
Filed:
July 26, 1996
Date of Patent:
October 15, 2002
Assignee:
The Regents of the University of California
Inventors:
Edward R. B. McCabe, Weiwen Guo, Thomas P. Burris, Eric Vilain
Abstract: The present invention provides a method of screening for a compound that binds to a selected nuclei acid comprising contacting compound fluorescently labeled by a fluorescent protein with a cell having a plurality of copies of the nucleic acid in an array such that the nuclei acid can be directly detected when bound by fluorescently labeled compound; and directly detecting the location of fluorescence within the cell, fluorescence aggregated at the site of the nuclei acid array indicating a compound that binds to the selected nucleic acid. In particular compounds such a transcription factors can be screened. Reagents for such method are provided including a mammalian cell having a plurality of steroid receptor response elements in an array such that the response element can be directly detected when bound by fluorescently labeled steroid receptor and a chimeric protein comprising a fluorescent protein fused to a steroid receptor.
Type:
Grant
Filed:
February 12, 1999
Date of Patent:
September 24, 2002
Assignees:
The United States of America as represented by the Department
of Health and Human Services
Abstract: Disclosed are methods for modulating apoptosis and altering programmed cell death events using novel Endo-SR gene compositions and the polypeptides encoded thereby. Also disclosed are methods for repairing DNA, modulating genetic recombination in a cell, and altering DNA rearrangement in a host cell. Also disclosed are methods for the design and isolation of peptidomimetics and other inhibitors of Endo-SR useful in the treatment of leukemias, lymphomas, and other cancers.
Type:
Grant
Filed:
December 11, 1998
Date of Patent:
September 24, 2002
Assignee:
The Regents of the University of California
Inventors:
Renato J. Aguilera, Christopher J. Lyon
Abstract: The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
Type:
Grant
Filed:
May 8, 2000
Date of Patent:
April 2, 2002
Assignee:
The Regents of the University of California
Inventors:
Charles L. Sawyers, Karen A. Klein, Owen N. Witte, Robert E. Reiter
Abstract: Macromolecule libraries constructed by transforming host cells with a collection of recombinant vectors that encode chimeras comprised of a carrier protein and a random peptide sequence are generated. The chimera is expressed intracellularly so that peptide inhibitors of biological pathways are identified through genetic selection. Peptides having a wide variety of uses such as therapeutic of diagnostic reagents, may thus be identified without any prior information on the structure of the desired target for the chimera.
Type:
Grant
Filed:
April 10, 1998
Date of Patent:
April 2, 2002
Assignee:
The Regents of the University of California
Inventors:
Andrew W. Murray, Dana L. Smith, Peter K. Sorger, Thea C. Norman
Abstract: The present invention is organ and tissue preservation solutions that provide improved viability of an organ such as a heart or lung, or portion of the organ, for storage and transplantation. In particular, a solution contains trehalose, magnesium sulfate, calcium chloride, heparin, dextran, nitroglycerin, adenosine, L-arginine, allopurinol, reduced glutathione, db-cylic AMP and potassium phosphate.
Type:
Grant
Filed:
April 27, 1999
Date of Patent:
April 2, 2002
Inventors:
David A. Bull, Bruce C. Reid, James C. Stringham, Shreekanth V. Karwande
Abstract: The invention provides novel compositions involving macromolecule-lipid complexes and methods for making them. These compositions and methods of the invention are significant improvements in the field of macromolecule-lipid complex processing, macromolecule targeting and delivery to various biological systems.
Type:
Grant
Filed:
June 26, 1998
Date of Patent:
March 19, 2002
Assignee:
The Regents of the University of California
Inventors:
Cyrus R. Safinya, Joachim Oskar Raedler, Ilya Koltover
Abstract: The present invention is methods for inhibiting the renin-induced production of TGF&bgr; using a renin inhibitory agent to reduce excess accumulation of extracellular matrix in tissue in a subject, and to the use of renin inhibitory agents and additional TGF&bgr; inhibitory agents to reduce TGF&bgr; production to treat and prevent fibrotic diseases.
Abstract: The present invention provides methods for inhibiting the growth of prostate tumor cells expressing Prostate Stem Cell Antigen (PSCA), the methods comprising administering to a patient a monoclonal antibody which binds specifically to the extracellular domain of PSCA in an amount effective to inhibit growth of the prostate tumor cells.
Type:
Grant
Filed:
March 10, 1998
Date of Patent:
July 31, 2001
Assignee:
The Regents of the University of California
Abstract: The present invention provides the molecular basis for cytokine induction of NF-&kgr;B-dependent immune and inflammatory responses, emphasizing a role for both NIK-NIK and NIK-IKK protein-protein interactions. A relatively small region of NIK selectively impairs the NIK-IKK interaction. The present invention provides a highly specific method for modulating NF-&kgr;B-dependent immune, inflammatory, and anti-apoptotic responses, based on interruption of the critical protein-protein interaction of NIK and IKK. The present invention provides methods for inhibiting NF-&kgr;B-dependent gene expression, using mutant NIK proteins. One embodiment of the present invention provides kinase-deficient NIK mutant proteins that inhibit activation of IKK. Another embodiment of the invention provides N-terminus NIK mutant proteins that bind IKK, thus inhibiting NIK/IKK interaction.
Type:
Grant
Filed:
February 25, 1999
Date of Patent:
July 24, 2001
Assignee:
The Regents of the University of California
Inventors:
Warner C. Greene, Xin Lin, Romas Gelezuinas
Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, bladder cancer and bone metastasis of prostate cancer. Antibodies specific to PSCA are used for diagnosis of these cancers.
Type:
Grant
Filed:
May 25, 1999
Date of Patent:
July 17, 2001
Assignee:
The Regents of the University of California
Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
Type:
Grant
Filed:
December 2, 1998
Date of Patent:
July 10, 2001
Assignee:
The Regents of the University of California
Abstract: A method for producing in vivo packaged recombinant adenovirus vectors is provided. The recombinant Ad vectors do not contain any Adenovirus genes and are therefore useful for gene therapy. The recombinant Adenovirus vectors are packaged in vivo using a helper virus which is itself very inefficiently packaged, providing a recombinant viral preparation with very little or no contamination with helper virus. In particular, the method makes use of a helper virus in which the packaging site can be easily excised in vivo by recombination mediated by a recombinase. The helper virus is also useful for the in vivo construction of new recombinant adenovirus vectors containing substitutions in the E1 or other adenoviral region.
Type:
Grant
Filed:
March 7, 1997
Date of Patent:
May 8, 2001
Assignee:
The Regents of the University of California
Abstract: This invention provides a method of treating an animal with pyrophosphate gout or osteoarthritis comprising administering an effective amount of a calcium antagonist, thereby reducing calcium pyrophosphate crystal deposition in the animal.
Type:
Grant
Filed:
July 9, 1999
Date of Patent:
April 24, 2001
Assignee:
The Regents of the University of California
Abstract: The present invention provides a bilayer structure for encapsulating multiple containment units. These containment units can attach or contain therapeutic or diagnostic agents that can be released through the bilayer structure. A suitable example of such a containment unit is a unilamellar or multilamellar vesicle.
Type:
Grant
Filed:
August 24, 1998
Date of Patent:
April 24, 2001
Assignee:
The Regents of the University of California
Inventors:
Joseph Zasadzinski, Scott Walker, Michael Kennedy